Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

From the author:

S. Miwa
European Respiratory Journal 2011 37: 723; DOI: 10.1183/09031936.00144410
S. Miwa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hirosei@za.tnc.ne.jp
  • Article
  • Info & Metrics
  • PDF
Loading

From the authors:

We are grateful to D. Aggarwal and co-workers for their comments on our recent article in the European Respiratory Journal 1. As they indicated, the serum procalcitonin (PCT) level could be altered under various conditions and we agree that clinical manifestations, sputum examination and radiological findings are the gold standard to differentiate pulmonary tuberculosis (PTB) from community-acquired pneumonia. Our data showed that serum PCT is not chronically elevated in PTB patients and that it is a poor prognostic marker when the level is above normal. Therefore, we also consider that serum PCT should be measured in selected cases in terms of its practical cost-benefit performance.

Footnotes

  • Statement of Interest

    None declared.

  • ©ERS 2011

REFERENCES

  1. ↵
    1. Ugajin M,
    2. Miwa S,
    3. Shirai M,
    4. et al
    . Usefulness of serum procalcitonin levels in pulmonary tuberculosis. Eur Respir J 2011; 37: 371–375.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 37 Issue 3 Table of Contents
European Respiratory Journal: 37 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
From the author:
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
From the author:
S. Miwa
European Respiratory Journal Mar 2011, 37 (3) 723; DOI: 10.1183/09031936.00144410

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
From the author:
S. Miwa
European Respiratory Journal Mar 2011, 37 (3) 723; DOI: 10.1183/09031936.00144410
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Reply: Central apnoeas, sympathetic activation and mortality in heart failure
  • Central apnoeas, sympathetic activation and mortality in heart failure
  • Comment: Combination therapy with long-acting bronchodilators and adverse events in COPD
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society